

Request for information under the Freedom of Information Act – 2021.843
Released – 7 June 2021

Thank you for your email received 24 May 2021 requesting information regarding isotretinoin.

Summary of your original request:

Please can you provide all information relating to reported adverse events/injuries/fatalities related to Isotretinoin?

Please provide all information relating to concerns raised either by patients, dermatologists, pharmacist and GP's?

Has Kent community trust ever conducted any investigation relating to Isotretinoin?

Do any of your dermatologists refuse to prescribe isotretinoin treatment?

Do any doctors across Kent refuse to refer patients to dermatologist for Isotretinoin treatment?

Do private hospitals/clinics have to report all know adverse events to the trust or are they a law unto themselves?

Has any legal action or complaints ever been made against the trust relating to Isotretinoin?

Has the trust ever implemented any safeguards relating to the prescribing of Isotretinoin?

How are patients monitored during and post treatment?

Patients must be past puberty before commencing Isotretinoin treatment - how is past puberty assessed?

***What is the duration of treatment and how is this tailored for the individual?
Does treatment continue until acne is clear or does it stop before or after acne has cleared?***

Are there any safeguards in place to ensure patients and their families are fully informed?

The Kent Community Health NHS Foundation Trust does not have any dermatology specialists; therefore we do not hold any information pertinent to your request.

Chairman John Goulston Chief Executive Paul Bentley

Trust HQ The Oast, Unit D, Hermitage Court, Hermitage Lane, Barming, near Maidstone, Kent ME16 9NT